Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. O...
Enregistré dans:
Auteur principal: | Stefan D. Anker |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/dd839f2ab3bf4e1e9d6388f31d4cd802 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Heart failure in diabetes: From an increased risk to a treatment target
par: Eberhard Standl
Publié: (2018) -
Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
par: Yury Ivanovich Suntsov
Publié: (2012) -
Role of incretin based therapies in the treatment of diabetic kidney disease
par: Paola Fioretto, et autres
Publié: (2018) -
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
par: Gagik R. Galstyan, et autres
Publié: (2016) -
Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
par: Sergey V. Kakorin, et autres
Publié: (2016)